Phase 1/2 Study Reports Final Results for CD123-Targeted Tagraxofusp in Relapsed/Refractory Myelofibrosis
核心洞察
Researchers published final safety and efficacy results from a phase 1/2 clinical trial evaluating tagraxofusp monotherapy in patients with relapsed/refractory myelofibrosis (搜索).
The study was led by Dr. Abdulraheem Yacoub and Dr. Naveen Pemmaraju, focusing on CD123 (搜索)-targeted therapy for this challenging hematologic malignancy.
Tagraxofusp represents a novel therapeutic approach targeting the CD123 (搜索) receptor in myelofibrosis (搜索) patients who have failed previous treatments.
A phase 1/2 clinical trial investigating tagraxofusp, a CD123 (搜索)-targeted therapy, in patients with relapsed/refractory myelofibrosis (搜索) has reached completion with final safety and efficacy results now published in Blood Neoplasia. The study represents a collaborative effort led by Dr. Abdulraheem Yacoub and Dr. Naveen Pemmaraju from MD Anderson Cancer Center.
Novel CD123-Targeted Approach
Tagraxofusp represents an innovative therapeutic strategy targeting the CD123 (搜索) receptor in myelofibrosis (搜索), a challenging myeloproliferative neoplasm. The monotherapy approach was specifically evaluated in patients with relapsed/refractory disease, addressing a significant unmet medical need in this patient population.
Research Leadership and Collaboration
The study was conducted under the leadership of Dr. Abdulraheem Yacoub and Dr. Naveen Pemmaraju, with Dr. Pemmaraju serving as Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center. The research team included multiple investigators: Haris Ali, Vikas Gupta, Eunice S. Wang, Mrinal M. Patnaik, Gary J. Schiller, Minakshi Taparia, Tariq I. Mughal, Ross Lindsay, Antonio Galleu, and Ira Gupta.
Clinical Trial Completion
The phase 1/2 study design allowed researchers to evaluate both the safety profile and therapeutic efficacy of tagraxofusp monotherapy in the relapsed/refractory myelofibrosis (搜索) setting. The completion of this clinical program provides important data for the myeloproliferative neoplasm research community, as indicated by its publication in the Blood Journals Portfolio.
Dr. Pemmaraju emphasized the collaborative nature of the research, describing it as "our brand new collaborative paper" and highlighting the focus on "patients with R/R Myelofibrosis (搜索)" in the context of myeloproliferative neoplasm research. The final results represent the culmination of this investigational CD123 (搜索)-targeted therapy program for this patient population.